Connect your AI

Enovis ENOV Payments For Derivative Instrument Financing Activities

Payments For Derivative Instrument Financing Activities at other companies

Merit Medical SystemsMMSI

$16.63M—

Other financials

Income statement

Revenue$589.2M+5.4%

Gross profit$365.5M+10.0%

Operating income$6.5M+114%

Net income-$8.8M+84.3%

EPS (diluted)-$0.15+84.7%

Balance sheet

Cash & equivalents$33.1M-13.9%

Total debt$1.4B-3.1%

Total equity$1.5B-43.6%

Total assets$3.8B-21.4%

Cash flow

Operating cash flow$24.0M+1,601%

CapEx$52.8M+22.1%

Free cash flow-$28.9M+35.7%

Valuation

Market cap$1.23B-28.4%

Enterprise value$2.55B-17.1%

P/S0.5×-0.3×

Profitability

Gross margin60.5%+4.0pp

Operating margin-47%+18.6pp

Net margin-49.9%+24.1pp

FCF margin-3.1%-1.1pp

Returns & leverage

Return on equity-55.5%-1,722pp

Debt / equity0.9×+0.4×

Current ratio2×-0.5×

Where this comes from

Reported directly by Enovis in its filing.

Tagged under the XBRL concept us-gaap:PaymentsForDerivativeInstrumentFinancingActivities.

The official record: Enovis’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →

Ask your AI about Enovis's payments for derivative instrument financing activities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Enovis's payments for derivative instrument financing activities?: Enovis (ENOV) reported payments for derivative instrument financing activities of $0 in Q4 2025.
What does payments for derivative instrument financing activities mean?: This represents cash outflows related to the settlement of derivative instruments that are specifically designated as financing activities, such as interest rate swaps or currency hedges on debt. It reflects the cost of managing the company's capital structure and interest rate exposure. Tracking these payments helps investors understand the true cost of servicing debt beyond stated interest rates.